Institute Pasteur Korea
Institut Pasteur Korea (IP-Korea) has been created in 2004 with the strategic focus on enabling technologies and therapeutics development in disease models pertaining to public health. In order to meet this goal, IP-Korea was one of the few world research centers to develop High Throughput Screening facilities based on internal and collaborative development of new screening assays. Today IP-Korea can take advantage of the diversity of its research, including biology groups, image mining, new microscopy development or medicinal and nano chemistry.
Institut Pasteur Korea (IP-Korea) has been created in 2004 with the strategic focus on enabling technologies and therapeutics development in disease models pertaining to public health. In order to meet this goal, IP-Korea was one of the few world research centers to develop High Throughput Screening facilities based on internal and collaborative development of new screening assays. Today IP-Korea can take advantage of the diversity of its research, including biology groups, image mining, new microscopy development or medicinal and nano chemistry.
IP-Korea is a part of the International Network of Pasteur Institutes, which allows IP-Korea the access to the research developed through the 28 other Institutes. In addition, IP-Korea has agreements with the French CNRS (Centre National pour le Recherche Scientifique), the KRICT (Korea Research Institute of Chemical Technology) and the KIST (Korea Institute of Science and Technology).
In the screening area, the goal of IP-Korea is to develop disease-based assays to visualize the physiological effect of the disease on the cellular level. To this end, IP-Korea has implemented the first worldwide uHTS platform from Evotec Technologies in a BSL-3 lab including an automatized confocal microscope (Opera) but also fluorescence/luminescence readers to perform High Content and HTScreens.
Institut Pasteur Korea is a non-profit organization based in Seoul, South Korea.